Literature DB >> 11817124

[Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases].

N Schleinitz1, V Veit, D Chouquet, V Seux, D Arnoux, D Mokart, B Lelong, M C Alessi, G Kaplanski, J R Harlé.   

Abstract

INTRODUCTION: Acquired factor V inhibitor is rare and clinical symptoms are quite variable. Bleeding is the leading symptom but some patients are asymptomatic. Several diseases or conditions are associated with factor V inhibitors. Various treatments have been attempted but randomized or prospective trials are not available. EXEGESIS: Here we report three cases of acquired factor V inhibitor. These reports highlight the clinical variability of this disorder. Pathogenesis and therapy with reference to the literature are discussed.
CONCLUSION: Factor V inhibitors are rare and associated to several diseases or conditions. Pathogenesis is still unclear except in patients exposed to bovine thrombin. The majority of the cases developed after surgery. In a few cases there is an association to a malignant or autoimmune disease. Plasmapheresis and platelet transfusions might be the best treatment in case of severe bleeding. High-dose intravenous immunoglobulin infusions have been used successfully in some cases and we report here their efficacy in two cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817124     DOI: 10.1016/s0248-8663(01)00477-5

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  1 in total

1.  Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review.

Authors:  Shinsaku Imashuku; Takeshi Hasegawa; Kagekatsu Kubo; Masaki Nakato; Midori Shima
Journal:  Int Med Case Rep J       Date:  2011-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.